Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Telormedix (Switzerland) a clinical-stage biopharmaceutical company focused on Toll-like receptor agonists for bladder cancer and autoimmune disease, closed a $8.3M Series B financing. Participants include Aravis Venture and Proquest Investments.

Vaxart (San Francisco, CA) a preclinical-stage developer of a platform vaccine technology focusing on oral delivery that leverages an adjuvant based upon a toll-like receptor, closed a $12.5M Series B financing. Participants include Care Capital.

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $4.6M Series B financing, bringing the total round to $27.5M. Participants include Roche Venture Fund, Enterprise Ireland, Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $22.9M Series B financing. Participants include Novartis Venture Funds, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

  

to top of page...